Serotonin mechanisms in pain and functional syndromes: Management implications in comorbid fibromyalgia, headache, and irritable bowel syndrome - Case study and discussion

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 18, Issue 4, 2004, Pages 31-45

  Smith, N Lee ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b HealthSouth Rehabilitation Hospital   (United States)

^c NONE   (United States)

Author keywords

5HT1; 5HT2; 5HT3; Antiepileptic; Anxiety; Atypical neuroleptic; Bipolar; Cation; Fatigue; Fibromyalgia; Headache; Hypersensitivity; Irritable bowel; Lamotrigene; Migraine; OCD; Pain; Pelvic pain; Quetiapine; Raynaud's; Serotonin

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CATION CHANNEL; CLOZAPINE; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PREGABALIN; QUETIAPINE; RISPERIDONE; ROFECOXIB; SEROTONIN 2 RECEPTOR; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZONISAMIDE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DRUG MECHANISM; EXPERIENCE; FEMALE; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; IRRITABLE COLON; MUSCLE SPASM; PAIN; RAYNAUD PHENOMENON; SEROTONIN RELEASE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; FEMALE; FIBROMYALGIA; HUMANS; HYPERSENSITIVITY; IRRITABLE BOWEL SYNDROME; MIGRAINE DISORDERS; PAIN; SEROTONIN; TREATMENT OUTCOME;

EID: 15244353336     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1300/J354v18n04_04     Document Type: Article

References (32)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646-57.
2. Barbanti P. Migraine. Cephalgia. 2001;21:295.
3. Kanieki R. Migraine. Neurology. 2002; Vol (Suppl 6): S15-S20.
4. Eisensamer B, Rammes G, Gimpl G, et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry. 2003;8:994-1007.
5. Sechi LA, Tedde R, Cassisa L, Pala A, Marigliano A, Masia S, Melis A. Evidence for a direct and non-receptor-mediated action of 5HT2 antagonists on transmembrane cation transport systems. Cardiovasc Drugs Ther. 1990;4 (Suppl 1):63-7.
6. Gillin JC, Salin-Pascual R, Velazquez-Moctezuma J, et al. Cholinergic receptor subtypes and REM sleep in animals and normal controls. Prog Brain Res. 1993;98: 379-87.
7. Drossman DA, Thompson WG. Irritable bowel syndrome: A graduated multicomponent treatment approach. Ann Int Med. 1992;116:1009-16.
8. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993;34:229-234.
9. Walker EA, et al. Comorbidity of gastrointestinal complaints, depression and anxiety in the epidemiological catchment area (ECA) study. Am J Meal. 1993;92(Suppl 1A):26-30.
10. Mayou R, Bryant B, Forfar C, Clark D. Non-cardiac chest pain and benign palpitations in the cardiac clinic. Br Heart J. 1994;72:548-53.
11. Sifiwardena A, Booker C, Pratt J, Kellum JM. Pathways of serotonin-induced electrolyte transport in rat distal colon. Surgery. 199;110(2):411-7; discussion 417-8.
12. Thor KB, Katofiasc MA, Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995;274(2): 1014-24.
13. Engel G, Hoyer D, Kalkman HO, Wick MB. Identification of 5HT2-receptors on longitudiual muscle of the guinea pig ileum. J Recept Res. 1984;4(1-6):113-26.
14. Rudnick A, Modal I, Zelikovski A. Fluoxetine-induced Raynaud's phenomenon. Biol Psychiatry. 1997;41:1218-21.
15. Kumagai S, Moriuobu A, Ozaki S, Nakao K, Ishida H. Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases. Ryumachi. 1998; 38(3):504-10.
16. 2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia. 1999;19:810-16.
17. Goadsby PJ, Lance JW. Physiopathology of migraine. Rev Prat. 1990 Feb. 11;40(5):389-93.
18. Lance JW. Fifty years of migraine research. Aust N Z J Med. 1988;18(3):311-7.
19. Sfikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesic-induced headache. Cephalgia. 1996(6):419-22.
20. Ghaemi SN. Recognizing bipolar disease in a unipolar world. Primary Psychiatry. 2001;8(2):28-34.
21. Manning JS, et al. The bipolar spectrum. Current Psychiatry. 2003;2(Suppl 3): 6-9.
22. Manning JS, Connor PD, Sahai A. The bipolar spectrum: A review of current concepts and implications for the management of depression in primary care. Arch Fam Med. 1998;7:63-71.
23. Strakowski SM, DelBello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs. 2002;15:701-8.
24. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(Suppl 2):41-4.
25. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28:83-96.
26. Keck PE, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 1998;59:(Suppl 6):74-81.
27. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo controlled prophylaxis study of lamotrigene in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61:841-50.
28. Solaro C, Ucalli MM, Ucalli A, et al. Low dose gabapentin combined with either lamotrigene or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44:45-8.
29. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: A placebo-controlled trial. J Clin Psychiatry. 2003;64(6):648-53.
30. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-11.
31. Bourin M, Auby P, Marcus RN, et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania. Poster presented at the 156th APA Annual Meeting; May 17-22, 2003; San Francisco, California.
32. Von Seggern RL, Mannix LK, Adelman JU. Rofecoxib in the prevention of perimenstrual migraine: An open-label pilot trial. Headache: The Journal of Head and Face Pain. 2004;44(2):165-6.